CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia
2018 ◽
Vol 2
(14)
◽
pp. 1738-1749
◽
Keyword(s):
Key Points CLL1-ADC targets both AML blasts and LSCs. Unlike CD33-ADC, CLL1-ADC does not affect normal HSCs.
2020 ◽
Vol 26
(3)
◽
pp. S33
2015 ◽
2018 ◽
Vol 25
(4)
◽
pp. 1358-1368
◽
Keyword(s):
2018 ◽
2019 ◽
Keyword(s):
2019 ◽
Keyword(s):
2017 ◽
Vol 17
(2)
◽
pp. 554-564
◽
Keyword(s):